• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » "It's Anticholinergic" - What does that mean?

"It's Anticholinergic" - What does that mean?

July 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Anticholinergic-speak is endemic in psychiatry. Since it’s unlikely to go away, we invite you to buff up your knowledge of acetylcholine (ACh) and to review the many ways in which it makes an appearance in clinical practice.

In medical school pharmacology courses, many of us were taught about cholinergic effects with the mnemonic “SLUD”: Salivation, Lacrimation, Urination, Defecation. I suggest augmenting this with a “C” standing for “Cognition.” If ACh facilitates SLUD-C, drugs that are anti-cholinergic – for example the tricyclics, Paxil (paroxetine), Cogentin (benztropine), Artane (trihexyphenydil), and Benadryl (diphenhydramine) -- are “Anti-SLUD-C.” This means that they cause dry mouth, dry eyes (and blurry vision), urinary retention, constipation, and confusion.

It’s a little more complicated, because there are actually two different ACh receptor types: muscarinic receptors, which mediate the SLUD part of SLUD-C, and nicotinic, which mediate the pro-cognitive, or “C” part of the mnemonic. We hear a bit about nicotinic receptors in promotional talks for Razadyne (galantamine), a cholinesterase inhibitor which has the added property of modulating nicotinic receptors. We’ll also hear a whole lot more about these receptors with the recent FDA approval of Pfizer’s Chantix (varenicline), a nicotinic receptor partial agonist that appears to be twice as good as Zyban (bupropion) for smoking cessation.

How does ACh relate to antipsychotic medications? We need to take a step back, and recall that anticholinergics were once a common treatment for Parkinson’s Disease, which is a condition caused by depletion of dopamine from specific brain regions. The fact that drugs such as Cogentin ease parkinsonian symptoms led to theory that there is a reciprocal relationship between ACh and dopamine (DA); what causes this reciprocity isn’t clear, but ACh may act to block DA reuptake in certain areas (J Neurosci 1999; 19(2):630-636).

At any rate, this balance between DA and ACh helps to explain why the most inherently anticholinergic of the conventional antipsychotics, such as Thorazine (chlorpromazine) and Mellaril (thioridizine), cause very little EPS. The potent antipsychotics, on the other hand, such as Haldol (haloperidol) are not inherently anticholinergic, and therefore require co-treatment with exogenous anticholinergics, such as Cogentin or Artane, in order to prevent EPS.

Finally, what about anticholinergics and the heart? While an anticholinergic effect can cause some increase in the heart rate, the cardiac problems caused by tricyclics and antipsychotics are not mediated by their anticholinergic properties. The orthostatic hypotension common with these agents is caused by anti-norepinephrine alpha blockade, and the cardiac conduction problems are caused by inherently toxic effects of the drug on the heart. So, please, don’t blame everything on anticholinergic effects!
General Psychiatry
    www.thecarlatreport.com
    Issue Date: July 1, 2006
    SUBSCRIBE NOW
    Table Of Contents
    Antidepressants: Does Mechanism Matter?
    Dopamine: Getting Reaquainted
    "It's Anticholinergic" - What does that mean?
    History of Neurotransmitters in Psychiatry
    The Father of Reuptake
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.